Table 1.
Ongoing immunotherapy clinical trials for patients with endometrial cancer.
| ClinicalTrials.gov identifier | Status | Interventions/alone or in combination | Phase |
|---|---|---|---|
| NCT02630823 | Active, not recruiting | Pembrolizumab (anti-PD-1) + Paclitaxel/Carboplatin/Radiation (standard of care) | I |
| NCT02725489 | Active, not recruiting | Durvalumab (anti-PD-L1) | II |
| NCT02728830 | Active, not recruiting | Pembrolizumab (anti-PD-1) | Early I |
| NCT02646748 | Active, not recruiting | Pembrolizumab (anti-PD-1) + itacitinib/INCB050465 | I |
| NCT02914470 | Active, not recruiting | Atezolizumab (anti-PD-L1) + cyclophosphamide/Carboplatin | I |
| NCT02521844 | Active, not recruiting | Pembrolizumab (anti-PD-1) + ETC-1922159 | I |